ATE414772T1 - Das hohe knochenmasse gen auf 11q13.3 - Google Patents

Das hohe knochenmasse gen auf 11q13.3

Info

Publication number
ATE414772T1
ATE414772T1 AT00941578T AT00941578T ATE414772T1 AT E414772 T1 ATE414772 T1 AT E414772T1 AT 00941578 T AT00941578 T AT 00941578T AT 00941578 T AT00941578 T AT 00941578T AT E414772 T1 ATE414772 T1 AT E414772T1
Authority
AT
Austria
Prior art keywords
methods
present
gene
bone mass
high bone
Prior art date
Application number
AT00941578T
Other languages
English (en)
Inventor
John Carulli
Randall Little
Robert Recker
Mark Johnson
Original Assignee
Oscient Pharmaceuticals Corp
Univ Creighton
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/544,398 external-priority patent/US6770461B1/en
Application filed by Oscient Pharmaceuticals Corp, Univ Creighton filed Critical Oscient Pharmaceuticals Corp
Application granted granted Critical
Publication of ATE414772T1 publication Critical patent/ATE414772T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/775—Apolipopeptides
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Toxicology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Addiction (AREA)
  • Hematology (AREA)
  • Reproductive Health (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Neurosurgery (AREA)
  • Obesity (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Nutrition Science (AREA)
  • Pregnancy & Childbirth (AREA)
  • Gynecology & Obstetrics (AREA)
AT00941578T 2000-04-05 2000-06-21 Das hohe knochenmasse gen auf 11q13.3 ATE414772T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/543,771 US6780609B1 (en) 1998-10-23 2000-04-05 High bone mass gene of 1.1q13.3
US09/544,398 US6770461B1 (en) 1998-10-23 2000-04-05 High bone mass gene of 11q13.3

Publications (1)

Publication Number Publication Date
ATE414772T1 true ATE414772T1 (de) 2008-12-15

Family

ID=32851157

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00941578T ATE414772T1 (de) 2000-04-05 2000-06-21 Das hohe knochenmasse gen auf 11q13.3

Country Status (7)

Country Link
US (2) US6780609B1 (de)
EP (1) EP1964921A3 (de)
AT (1) ATE414772T1 (de)
DE (1) DE60040870D1 (de)
DK (1) DK1268775T3 (de)
ES (1) ES2316370T3 (de)
ZA (1) ZA200207883B (de)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6770461B1 (en) * 1998-10-23 2004-08-03 Genome Therapeutics Corporation High bone mass gene of 11q13.3
US7514594B2 (en) * 2001-05-11 2009-04-07 Wyeth Transgenic animal model of bone mass modulation
EP1711606A2 (de) * 2004-01-20 2006-10-18 Isis Pharmaceuticals, Inc. Modulation der expression des glucocorticoidrezeptors
EP2566892B1 (de) 2010-05-06 2017-12-20 Novartis AG Zusammensetzungen und verfahren zur verwendung von therapeutischen antikörpern gegen ldl-assoziiertes protein 6 (lrp6)
PH12012502193A1 (en) 2010-05-06 2021-08-09 Novartis Ag Compositions and methods of use for therapeutic low density lipoprotein - related protein 6 (lrp6) multivalent antibodies
ES2666856T3 (es) 2011-11-04 2018-05-08 Novartis Ag Proteína 6 relacionada con lipoproteínas de baja densidad (LRP6) - constructos extensores de la vida media

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL154598B (nl) 1970-11-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking.
US3817837A (en) 1971-05-14 1974-06-18 Syva Corp Enzyme amplification assay
US3939350A (en) 1974-04-29 1976-02-17 Board Of Trustees Of The Leland Stanford Junior University Fluorescent immunoassay employing total reflection for activation
US3996345A (en) 1974-08-12 1976-12-07 Syva Company Fluorescence quenching with immunological pairs in immunoassays
US4277437A (en) 1978-04-05 1981-07-07 Syva Company Kit for carrying out chemically induced fluorescence immunoassay
US4275149A (en) 1978-11-24 1981-06-23 Syva Company Macromolecular environment control in specific receptor assays
US4366241A (en) 1980-08-07 1982-12-28 Syva Company Concentrating zone method in heterogeneous immunoassays
CA1188246A (en) 1981-08-31 1985-06-04 Jerry L. Gregory Immobilized microbe recycle apparatus
NZ207394A (en) 1983-03-08 1987-03-06 Commw Serum Lab Commission Detecting or determining sequence of amino acids
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4973666A (en) 1987-11-06 1990-11-27 Washington Research Foundation Peptide fragments containing HP and LP cross-links
US5283173A (en) 1990-01-24 1994-02-01 The Research Foundation Of State University Of New York System to detect protein-protein interactions
IL103059A0 (en) 1991-09-30 1993-02-21 Boehringer Ingelheim Int Conjugates for introducing nucleic acid into higher eucaryotic cells
US5252479A (en) 1991-11-08 1993-10-12 Research Corporation Technologies, Inc. Safe vector for gene therapy
TW366342B (en) 1992-07-28 1999-08-11 Lilly Co Eli The use of 2-phenyl-3-aroylbenzothiophenes in inhibiting bone loss
WO1997012903A1 (en) 1995-10-04 1997-04-10 Warner-Lambert Company Compounds, compositions and methods for inhibiting the binding of proteins containing an sh2 domain to cognate phosphorylated proteins
US5691153A (en) * 1996-09-06 1997-11-25 Creighton University Genetic markers to detect high bone mass
US5849902A (en) 1996-09-26 1998-12-15 Oligos Etc. Inc. Three component chimeric antisense oligonucleotides
DE69837542T2 (de) 1997-04-15 2008-01-31 Merck & Co, Inc. Ldl-rezeptor
US6555654B1 (en) 1997-04-15 2003-04-29 The Wellcome Trust Limited As Trustee For The Wellcome Trust LDL-receptor
BE1011331A6 (fr) 1997-08-20 1999-07-06 Univ Catholique De Louvain Hal Polypeptide associe au peroxysome, sequence nucleotidique encodant ledit polypeptide et leur utilisation dans le diagnostic et/ou le traitement de maladies ou de lesions pulmonaires.
FR2768747B1 (fr) 1997-09-19 2000-12-01 Pasteur Institut Acides nucleiques, cellules recombinantes, et procede de preparation de compositions immunogenes
JP2002506873A (ja) 1998-03-18 2002-03-05 アリアド・ファーマシューティカルズ・インコーポレイテッド 複素環式シグナル伝達阻害剤、それを含む組成物
DE60129433T2 (de) * 2000-05-26 2008-04-17 Oscient Pharmaceuticals Corp., Waltham Regulation des lipidniveaus über die gene zmax1 oder hbm
WO2002092000A2 (en) * 2001-05-11 2002-11-21 Genome Therapeutics Corporation Hbm variants that modulate bone mass and lipid levels
US8637506B2 (en) * 2003-09-22 2014-01-28 Enzo Biochem, Inc. Compositions and methods for bone formation and remodeling
KR102371587B1 (ko) 2015-05-22 2022-03-07 현대자동차주식회사 횡단보도 인식 결과를 이용한 안내 정보 제공 장치 및 방법

Also Published As

Publication number Publication date
EP1964921A3 (de) 2008-12-03
EP1964921A2 (de) 2008-09-03
ES2316370T3 (es) 2009-04-16
US20050142617A1 (en) 2005-06-30
DK1268775T3 (da) 2009-03-16
US6780609B1 (en) 2004-08-24
ZA200207883B (en) 2004-01-27
DE60040870D1 (de) 2009-01-02

Similar Documents

Publication Publication Date Title
MXPA03010077A (es) Abonadora de siembra a voleo con deflector movible.
WO2002092764A3 (en) Transgenic animal model of bone mass modulation
CY1108998T1 (el) Πρωτεϊνες που δεσμευονται με οστεοπροτεγερινη και υποδοχεις
ATE378407T1 (de) Morphogene protein-spezifische zelloberflächenrezeptoren und ihre verwendungen
DK1005540T3 (da) IKK-beta-proteiner, nukleinsyrer og fremgangsmåder
EA199900939A1 (ru) Остеопротегерин-связывающие белки и рецепторы
ATE371727T1 (de) Kdr, ein menschlicher tyrosin kinase rezeptor
MX9606463A (es) Secuencias de nucleotido de las cepas pestivirus, polipeptidos codificados por estas secuencias y usos de los mismos para la diagnosis y prevencion de infecciones con pestivirus.
MXPA02009791A (es) El gen de alta masa osea de 11q13.3.
DE69435136D1 (de) Geneexpression der Neurofilamentproteine und Nachweis der alzheimeschen Erkrankung
ATE414772T1 (de) Das hohe knochenmasse gen auf 11q13.3
Smith A C. elegans gene encodes a protein homologous to mammalian calreticulin
DE60129433D1 (de) Regulation des lipidniveaus über die gene zmax1 oder hbm
DE69233263D1 (de) Nukleotidsequenzen und gegen cycloheximid resistente proteine
EA200000845A1 (ru) Ген, кодирующий новый маркер рака
DE69534705D1 (de) Dickdarm spezifische gene und proteine
Dumoulin et al. Orientation of the LexA DNA-binding motif on operator DNA as inferred from cysteine-mediated phenyl azide crosslinking.
ATE483019T1 (de) Aus einem neuroblastom in stufe 4s isoliertenukleinsäuren
Gibson et al. Non-muscle and smooth muscle myosin light chain kinases: no end in sight
Kim et al. Identification and Phylogenetic Analysis of Schizophrenia Associated Retrovirus (SZRV) Element in the Human GenBank Database
ATE430156T1 (de) Tumor-oberflächenprotein und sein entsprechender oberflächenrezeptor auf natürlichen killerzellen

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties